MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston Sells 3,000 Shares

MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston sold 3,000 shares of the stock in a transaction on Monday, January 27th. The stock was sold at an average price of $4.64, for a total value of $13,920.00. Following the transaction, the director now owns 141,950 shares of the company’s stock, valued at $658,648. This represents a 2.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

John Joseph Johnston also recently made the following trade(s):

• On Thursday, December 26th, John Joseph Johnston sold 3,000 shares of MaxCyte stock. The stock was sold at an average price of $4.01, for a total transaction of $12,030.00.

MaxCyte Trading Down 1.1 %

Shares of MaxCyte stock opened at $4.59 on Friday. The stock has a market capitalization of $485.21 million, a price-to-earnings ratio of -13.50 and a beta of 1.29. The firm’s 50-day moving average price is $4.23 and its two-hundred day moving average price is $4.09. MaxCyte, Inc. has a 1-year low of $3.16 and a 1-year high of $5.29.

MaxCyte (NASDAQ:MXCT) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02. The firm had revenue of $8.16 million during the quarter, compared to the consensus estimate of $7.50 million. MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. During the same quarter in the previous year, the company posted ($0.11) EPS. As a group, equities research analysts predict that MaxCyte, Inc. will post -0.42 EPS for the current year.

Institutional Investors Weigh In On MaxCyte

A number of hedge funds have recently added to or reduced their stakes in MXCT. Marshall Wace LLP bought a new stake in shares of MaxCyte during the second quarter valued at approximately $1,959,000. ArrowMark Colorado Holdings LLC boosted its position in MaxCyte by 13.8% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,394,947 shares of the company’s stock valued at $5,426,000 after buying an additional 169,250 shares during the last quarter. Mudita Advisors LLP increased its stake in shares of MaxCyte by 5.6% in the 3rd quarter. Mudita Advisors LLP now owns 3,153,441 shares of the company’s stock valued at $12,267,000 after buying an additional 167,101 shares during the period. Gagnon Securities LLC raised its position in shares of MaxCyte by 234.1% during the fourth quarter. Gagnon Securities LLC now owns 197,326 shares of the company’s stock worth $821,000 after acquiring an additional 138,257 shares during the last quarter. Finally, Barclays PLC boosted its holdings in MaxCyte by 329.3% in the third quarter. Barclays PLC now owns 165,765 shares of the company’s stock valued at $645,000 after acquiring an additional 127,156 shares during the last quarter. Institutional investors own 68.81% of the company’s stock.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.